At Newpath, we emphasize teamwork. We’ve brought together professionals with diverse backgrounds to create the next powerful wave of life science companies. Together, we work to push science forward and to help bring meaningful treatments to patients.
Dr. Cahill leads all operations at Newpath, focusing on the formation, strategy, and development of the firm’s investments. He concentrates on uniquely aligning interests between academic scientists, investors, and management teams. He actively sits on the board of all Newpath’s investments.
Dr. DeSouza performs the firm’s scientific discovery and diligence. He utilizes his healthcare and clinical experience to develop strategic scientific strategies for new company formations and throughout the firm’s active portfolio companies.
Mr. Ferraro concentrates on the firms’ investment strategy through assisting company formation diligence, including scientific, legal, and financial development. Through his role he supports Newpath’s academic scientists in bridging the gap between scientific and business strategy towards company creation.
Mr. McGraw focuses on the firms’ financial strategy, reporting and operations for the investment funds, as well as managing the firm’s management company. In addition, Mr. McGraw leads the financial creation and operations of Newpath’s early-stage portfolio companies.
Mrs. Denman manages the operations and administrative support at Newpath.
Ms. Frank works on the firms’ financial reporting and analysis for the investment funds. In addition, she plays an integral role in assisting the financial launch and growth of Newpath’s early-stage portfolio companies.
Ms. Scales assists the operations and administrative duties within the Newpath office and amongst the team.
Dr. Yadegar reviews and consults on medical and scientific diligence within Newpath. He brings his active clinical experience and knowledge to assist Newpath in supporting the firm’s portfolio companies.
